There’s a lot to be optimistic about in the Services sector as 2 analysts just weighed in on Marchex (MCHX – Research Report) and Augmedix (AUGX – Research Report) with bullish sentiments.
Marchex (MCHX)
Roth Capital analyst Darren Aftahi reiterated a Buy rating on Marchex today and set a price target of $3.00. The company’s shares closed last Tuesday at $1.95.
According to TipRanks.com, Aftahi is a 5-star analyst with an average return of
Marchex has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.
See the top stocks recommended by analysts >>
Augmedix (AUGX)
Maxim Group analyst Allen Klee maintained a Buy rating on Augmedix yesterday and set a price target of $4.00. The company’s shares closed last Tuesday at $1.52, close to its 52-week low of $1.41.
According to TipRanks.com, Klee is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Augmedix with a $4.25 average price target, a 183.3% upside from current levels. In a report issued on August 1, B.Riley Financial also maintained a Buy rating on the stock with a $4.50 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MCHX:
- Greenwave Reports Record Q2 2022 Revenues and Cashflows from Operations and Announces it Will Open Two New Metal Recycling Facilities Following Listing on Nasdaq
- Trulieve Cannabis (TCNNF) Gets a Buy from Needham
- DZ BANK AG Sticks to Its Hold Rating for Continental Aktiengesellschaft (CTTAF)
- J.P. Morgan Reaffirms Their Buy Rating on Nike (NKE)
- UMH Properties (UMH) Receives a Hold from Colliers Securities
